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Objective: To evaluate an entirely outpatient-based program of pulmonary rehabilitation in 
patients with chronic obstructive pulmonary disease COPD, using St.George’s Respiratory 
questionnaire (SGRQ), the 6-minutes walking test (6-MWT) and BODE index as the primary 
outcome measures.
Methods: A prospective, parallel-group controlled study of an outpatient rehabilitation program 
in 80 patients with COPD (67 men and 13 women; mean age 64.8 ± 10.6 years; FEV1, 42.8% 
± 7.6% of the predicted value. The active group (n = 40) took part in a 14-week rehabilitation 
program [3 h/wk, 1.5 h of education and exercise and 1.5 h of cycling]. The control group 
(n = 40) was reviewed routinely as medical outpatients. The following evaluations were carried 
out at study entry and after14 weeks: (1) pulmonary function studies; (2) 6-minutes walking 
test 6MWT; (3) quality of life; and (4) BODE index.
Results: The following patients completed the study: 35 patients (87.5%) from the active 
group (mean age, 63.7 ± 11.9 years; mean forced expiratory volume in one second (FEV1), 
41.9 ± 2.6% of the predicted value); and 36 patients (88%) from the control group (mean age, 
65.9 ± 10.3 years; mean FEV1, 43.33 ± 3.6% of the predicted value). We found no changes in 
pulmonary function parameters in the active group and the control one at 14weeks. On the other 
hand, there were signiﬁ  cant changes within the components of the SGRQ (12.3 for the score 
total) for the patients of the active group but not for the patients of the control one (only 1.5 
for the score total), we observed also a signiﬁ  cant increase in the distance of the 6-MWT in the 
patients of the active group but not for the patients of the control one, and ﬁ  nally a decrease of 
two points (from 6 to 4) was noted in the score of the active group’s BODE index without any 
change in the control group’s one.
Conclusion: An outpatient-based of 14-week rehabilitation program signiﬁ  cantly improved the 
quality of life and exercise tolerance without any change in the pulmonary function in patients 
with moderate COPD, and there was also a large decrease in the risk of death in rehabilitated 
patients as measured using the BODE index.
Keywords: COPD, quality of life, pulmonary rehabilitation, 6-minute walking test, BODE 
index
Introduction
Chronic obstructive pulmonary disease (COPD), which is deﬁ  ned as a disease state 
characterized by progressive airﬂ  ow limitation that is not fully reversible, and is associ-
ated with an abnormal inﬂ  ammatory response of lungs to noxious particles or gases, 
primarily cigarette smoke (Celli et al 2004; Global Initiative for Chronic Obstructive 
Lung Disease 2005), is a highly prevalent disease that has a large impact on quality 
of life for patients and their families and kills millions of people worldwide (Global 
Initiative for Chronic Obstructive Lung Disease 2005; Strong et al 2005). In 2004, 
the American Thoracic Society/European Respiratory Society guidelines introduced 
in the deﬁ  nition the concept that, although COPD affects the lungs, it also produces 
signiﬁ  cant systemic consequences (Celli et al 2004).International Journal of COPD 2008:3(1) 156
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Patients with COPD are markedly inactive in daily 
life and are often characterized by a downward spiral of 
symptom-induced inactivity, leading to deconditioning and 
muscle weakness (Rennard et al 2003), which results in 
spending less and less time walking and standing compared 
with sedentary healthy elderly subjects (Pitta et al 2005).
Systemic effects of COPD involve respiratory and skel-
etal muscles (Sin et al 2004; Agusti et al 2005; MacNee 
et al 2005; Man et al 2005; Oudijk et al 2005; Tapson et al 
2005; Wouters et al 2005; Yasuda et al 2005). In patients 
with COPD, the functional impairment of the diaphragm 
is associated with loss of myosin heavy chain and elevated 
level of ubiquitin-conjugated proteins, suggesting acceler-
ated muscle protein degradation. In addition, the remaining 
contractile proteins in these ﬁ  bres are dysfunctional, and 
the calcium sensitivity of force generation is reduced. These 
abnormalities could all contribute to muscle weakness, par-
ticularly at sub-maximal activation, even in patients with 
mild to moderate COPD (Ottenheijm et al 2005).
Abdominal muscle strength in the presence of quadriceps 
weakness is preserved in stable outpatients with COPD, sug-
gesting that disuse and consequent deconditioning contribute 
to the development of quadriceps muscle weakness, and/or 
that activities like postural one protect the abdominal muscles 
from systemic myopathic process (Man et al 2005).
Skeletal muscle dysfunction has now been widely 
accepted in COPD, and has been reviewed in several excel-
lent reviews (American Thoracic Society 1999; Debigare 
et al 2001; Laghi et al 2003). Skeletal muscle atrophy or 
weakness is clearly a negative prognostic factor (Decramer 
et al 1997; Decramer et al 1998; Marquis et al 2002) and 
requires appropriate action. The potential for at least partial 
reversibility of this dysfunction is believed to be an impor-
tant determinant of the physiological gain achieved with 
pulmonary rehabilitation.
Pulmonary rehabilitation is now considered to be a main-
stay of treatment for patients with chronic lung disease; it has 
been shown to result in many beneﬁ  ts, including improve-
ment in exercise performance, reduction of dyspnoea, 
improvement in health- related quality of life, and reduction 
in health-care utilization (Ries et al 1995; American College 
of Chest Physicians 1997; American Thoracic Society 1999; 
Verrill et al 2005). Key elements include a multidisciplinary 
approach to care with a focus on the individual patients 
through education, exercise, and psychosocial interven-
tions. Appropriate candidates for pulmonary rehabilitation 
are symptomatic patients with chronic lung disease who are 
aware of their disability and are motivated to participate 
actively in their health care. In other words, according to 
the Global Initiative for Chronic Lung Disease consensus 
statement on the management of COPD (Fabbri et al 2003), 
pulmonary rehabilitation should be considered for patients 
with a forced expiratory volume in one second (FEV1) of 
80% of the predicted value.
Objective
This study aims to evaluate the effects of an outpatient 
program of physical exercise used especially for the lower 
limbs (quadriceps muscle) and with an ergo-metric-bicycle, 
this program was designed to improve the exercise capacity 
and the quality of life in patients with moderate to severe 
COPD, in addition to evaluate the effect of this program on 
the mortality rate in this group of patients using BODE index 
(Bartolome et al 2004).
Materials and methods
Patients
Patients accepted in the study were known to the respiratory 
team at the hospital as having long-standing airway disease, 
classiﬁ  ed as COPD, and were examined at an outpatient 
clinic by a respiratory specialist who discussed the study in 
the course of assessing their condition and progress. All had 
had their therapy optimized. Patients were assessed as to their 
ability to comply with the requirements of the program, spe-
ciﬁ  cally the time and travel commitments involved. Among 
our 80 patients, there were 62 smokers, among these smokers 
43 had given up smoking one month before the beginning of 
the program, and the remaining 19 smokers were prepared to 
make an active effort to stop smoking during the proposed 
program, but non of them have absolutely quitted by the end 
of the program.
Contraindications to entry in to the study were unstable 
medical conditions, such as congestive cardiac failure, 
cor-pulmonale, malignancy, or cerebrovascular accident. 
We also excluded the patients with sleep apnea syndrome. 
None had previously taken part in the supervised respiratory 
rehabilitation program.
Patients were assessed using a standard 6-min walk, 
spirometry, plethismography, and each completed the SGRQ. 
All of these tests were supervised by a blinded observer who 
subsequently repeated this assessment before the study and 
at the end of the study (0 and 14 weeks). BODE index was 
also computed at the study entry and at the end of study for 
all patients. At the study entry, patients were randomized 
to either the rehabilitation program of 40-sessions for a 
total period of 14weeks or to routine outpatient attendance International Journal of COPD 2008:3(1) 157
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at 4-month intervals. Randomization was in blocks of 10, 
using random numbers.
All patients were informed of the objectives and design 
of the study and gave their informed consent to participate 
in this rehabilitation program which was approved by our 
local institutional review board.
Rehabilitation program
The 14-week outpatient-based rehabilitation program 
involved three visits per week: a 30-min education and 
exercises visit and a 30-min session of cycling on an ergo-
metric bicycle.
During the course of the program, patients underwent 
an initial medical assessment and then received information 
from a team composed of a physiotherapist, a respiratory 
specialist nurse, and a dietician.
We began with an intensity of 25 watts and we increased 
the intensity by 5 watts each week until reaching the intensity 
of 40 watts, at which time, the VO2 max was achieved for 
the patient. The aim after that was to reach the intensity of 
80% of the VO2 max of each patient.
Physiotherapy
The physiotherapist discussed breathing problems and 
emphasized exercise regime. At the 30-min exercise there 
was 5-min warm-up period, 10-min of aerobic activity and 
15-min cool-down period. The aerobic activity included 
diagonal arm raises, arm abduction into elevation and 
reverse, and arm abduction, forward ﬂ  exion, and reverse; 
and straight leg rises.
Dietary assessment and advice
Each patient’s body mass index (BMI) and dietary history 
were assessed, and progress in the body weight change was 
assessed every week.
Parameters studied
Spirometry
A Pneumocheck(R) spirometer (ms medi-soft module 5500, 
USA) was used, and all procedures were carried out accord-
ing to ATS guidelines (American Thoracic Society 1995). 
The parameters evaluated were: forced vital capacity (FVC), 
FEV1, the FEV1/FVC ratio, and we assessed the residual 
volume (RV) by plethysmography (medi-soft).
Quality of life
Patients were evaluated with the Saint George’s Respiratory 
Questionnaire (SGRQ), which is speciﬁ  cally designed for 
respiratory disease (Jones et al 1992). A trained interviewer 
administered the questionnaire and if a patient failed to 
understand a question, the interviewer repeated it until the 
patient chose an alternative.
Walking test
Each patient was submitted to a 6-minute walking test 
(6MWT), conducted in a closed corridor of 30 meter. Each 
test was given twice, with a 10–15 minute interval between 
the two. During the test the patient was instructed to walk 
as fast as possible for six minutes and to decrease speed or 
interrupt the test if experiencing severe dyspnoea or any 
other limiting discomfort. The examiner gave patients verbal 
encouragement once per minute using standard motivational 
phrases intended to ensure that patients walked as fast as 
possible throughout the test. Heart rate, dyspnoea, and partial 
oxygen saturation were measured before and after each test. 
A trained investigator who did not have access to previous 
evaluations applied the test or information on the group the 
patient belonged to.
Bode index
It is a multidimensional index which includes four factors 
that predict the risk of death: the body mass index B, the 
degree of air ﬂ  ow obstruction O, the functional dyspnoea D, 
and exercise capacity E as assessed by the six-minutes walk 
test (Bartolome et al 2004).
Computation of BODE index
For each threshold value of FEV1, distance walked in six 
minutes, and score of the MMRC dyspnoea scale as shown 
in Table1, the patients received points ranging from 0 (lowest 
Table1 Variables and point values used for the computation 
of the body mass index, degree of airﬂ  ow obstruction 
and dyspnoea, and exercise capacity (BODE) index 
Variable  Points on BODE index
 0  1  2  3
FEV1(% of predicted)**   or= 65  50–64  36–49   or= 35
Distance walked   or= 350  250–349  150–249   or= 149
in 6 min (m) 
MMRC dyspnea§ 0–1 2 3 4
Body mass index§§  21  21  
Notes: *The cutoff values for the assignment of points are shown for each vari-
able; The total possible values range from 0 to 10. FEV1 donated forced expiratory 
volume in one second; **The FEV1 categories are based on stages identiﬁ  ed by 
the American Thoracic Society; §Scores on the modiﬁ  ed Medical Research Council 
(MMRC) dyspnoea scale can range from 0 to 4, with a score of 4 indicating that 
the patient is too breathless to leave the house or becomes breathless when 
dressing or undressing; §§The values for body-mass index were 0 or 1 because of 
the inﬂ  ection point in the inverse relation between survival and body mass index 
at a value of 21.International Journal of COPD 2008:3(1) 158
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value) to 3 (maximal value). For body mass index, the values 
were 0 or 1, because of the unique relation between body 
mass index and survival among COPD patients. The points 
for each variable were added, so that the BODE index ranged 
from 0 to 10 points, with higher scores indicating a greater 
risk of death.
Statistical analysis
To determine whether subjects altered their parameters of 
pulmonary function like (FEV1/FVC, FEV1, and RV) before 
the physical exercise program were compared with their 
respective values 14 weeks afterwards.
The scores of SGRQ were obtained before the program and 
14 weeks later. All data are reported as means ± standard devia-
tion (S.D.) and p  0.05 was accepted as indicating a signiﬁ  cant 
change. Statistical analysis was performed using a statistical 
software program (SAS, version 8.2; SAS Institute).
An unpaired t-test was done of the difference between the 
baseline measurement and the measurement at 14 weeks, and 
95% conﬁ  dence intervals (CIs) were constructed for the dif-
ference between the mean changes in each of the two groups. 
In addition, paired t-tests were performed within each group 
to assess whether changes from baseline had occurred.
Results
Eighty patients who were believed to fulﬁ  l the criteria of 
the study were approached, and they agreed to provisional 
assessment and detailed discussion of the requirements of the 
study. Of these, 40 were randomized to the active group; 40 
were randomized to the control group. Five patients in the 
active group were excluded from analysis (3 patients were not 
only COPD (association with sleep apnea syndrome n = 3) 
and 2 patients were excluded because of their absence for 
4 consecutive sessions, and 4 patients were also excluded 
from the control group (2 patients had a cardiac problem 
during the ﬁ  rst month of the program and 2 patients had an 
association with sleep apnea syndrome) leaving 71 patients 
with COPD recruited to the study.
The mean FEV1 was (41.9%  ± 2.6%) in the active group 
versus (43.33% ± 3.6%) in the control group; the mean FVC 
was (86.1% ± 17.8%) in the active group versus (78.7% ± 3.5) 
in the control group. There was no signiﬁ  cant difference in 
sex distribution, age, or spirometry measures between the 
two groups (Table 2).
Quality of life measures
The SGRQ is a 76-weighted-item questionnaire, in which 
results are expressed for symptoms, activity, impacts on 
daily life, and an integrated total score. The groups were 
well matched for SGRQ scores and walking distances on 
study entry (Table 3).
The SGRQ integrated total scores for control group were 
(58.5 ± 3.7) at study entry and (53.1 ± 3.0) at 14 weeks (end 
of the study). For the control group, there were no signiﬁ  -
cant differences over the 14-week study period in scores for 
symptoms, impacts on daily life, activity, or integrated total 
scores (Table 4).
The SGRQ integrate total scores for the active group were 
(59.6 ± 3.2) at the study entry (n = 35) which closely matched 
the scores in the control group. At 14 weeks, the mean SGRQ 
total score was (47.3 ± 2.6). This was signiﬁ  cant different 
from baseline (p  0.05, paired t- test) with a mean reduction 
of total scores of 12.8. The changes from baseline in SGRQ 
total score at 14 weeks were compared between the active 
and control groups: the mean difference was a reduction of 
10.3 in favor of the active group (p  0.05).
A secondary analysis of the components of the total 
SGRQ, namely symptom score, activity score, and impact on 
daily living score revealed signiﬁ  cant reductions in all three 
components in the active group (for each of them p  0.05), 
and that the change in total scores could not be attributed 
principally to a change in any one component.
Walking distance
The mean distances walked over 6 min, supervised by a 
physiotherapist blinded to the subject randomization, are 
summarized in Table 5. The active group had a longer 
Table 2 Patient characteristics
Characteristics   Active group  Control group
Male/female gender, No.  34/6  33/7
Age, yr  63.7 ± (11.9)  65.9 ± (10.3)
BMI 24.2  ± (6.4)  25.6 ± (4.3)
FEV1, % predicted  41.9 ± (2.6)  43.33 ± (3.6)
FVC, % predicted  86.1 ± (17.8)  78.7 ± (3.5)
Notes: Data are presented as mean ± SD unless otherwise indicated.
Table 3 Baseline SGRQ scores and walking distances for active 
and control groups
Parameters Active  group  Control  group
 (n  = 35)  (n = 36)
Symptom score  38.2 ± (2.6)  42.33 ± (2.9)
Activity scores  63.3 ± (2.1)  64.83 ± (2.4)
Impact on daily living score  52.1 ± (3.2)  47.3 ± (3.3)
Total integrated score  59.6 ± (3.2)  58.5 ± (3.7)
Walking distance, m  284 ± (18)  273 ± (19)
Notes: Data are presented as mean ± SD.International Journal of COPD 2008:3(1) 159
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6-min mean distance at study entry, although it did not 
differ signiﬁ  cantly from that of the control group. There 
was a mean increase of more than 54 m (a signiﬁ  cant 
increase; Redelmeier et al 1997) in the active group after 
14 weeks, which was signiﬁ  cantly greater than the mean 
change in the control group (p  0.05). In other words, 
68% of the patients in the active group presented a sig-
niﬁ  cant improvement in the distance of walking test at the 
end of 14 weeks.
Pulmonary function
There was no signiﬁ  cant change in any of the parameters of 
the pulmonary function, neither within the active group nor 
within the control group as shown in Table 6.
BODE index
A large decrease of two points (from 6 to 4) in the score of 
BODE index for the patients of the rehabilitation group was 
noted, the largest part of this decrease was due to the decrease 
in the dyspnoea ,whereas we did not ﬁ  nd such a decrease or 
any other changes in the BODE index of the patients of the 
control group as shown in Table 7.
Discussion
Our current study has shown that the physical exercise pro-
gram which was designed with the objective of increasing 
the strength of the lower limb muscles by using a bicycle 
improves the quality of life and sub-maximal exercise capac-
ity in patients with moderate COPD.
Even though there have been signiﬁ  cant advances in the 
understanding and management of COPD (Fishman et al 
2005; Shapiro et al 2005), suggesting that the disease may 
be largely preventable, it remains only marginally treatable. 
This is probably because COPD is due to a slowly progressive 
destructive process of the lung that is poorly reversible when 
manifested clinically and because it has systemic effects 
and frequent comorbidities that should be managed more 
comprehensively (Boyd et al 2005).
Thus, management of patients with COPD includes edu-
cation, preventive care, smoking cessation, pharmacological 
and oxygen therapy, and pulmonary rehabilitation (Lacasse 
et al 1996).
Pulmonary rehabilitation is an effective treatment option 
for COPD (Troosters et al 2005), may improve exercise 
capacity, at least in part, by reducing systemic oxidative stress 
(Mercken et al 2005), also exert ional dyspnoea is consist-
ently reported to be reduced after pulmonary rehabilitation 
(Gigliotti et al 2003). The reduction in dyspnoea is mediated 
through the reduced ventilatory requirements at identical 
work rates and identical oxygen consumption.
The clinical relevance of the beneﬁ  t of pulmonary reha-
bilitation is illustrated by improved functional capacity, as 
measured by the 6-minute walk test. The minimal clinically 
important difference of the 6-minute walking test has been 
estimated to be 54 m (Redelmeier et al 1997). This test 
(6MWT) is used to assess the functional status of patients 
with COPD. Over time it has proved to be reliable, objective, 
inexpensive and easy to apply regardless of the patient’s age 
and educational level (Bittner et al 1993). It has been shown 
to predict survival post-pulmonary rehabilitation (Gerardi 
et al 1996).
Thus, we found that most of our patients (within the active 
group) represented an increase in the distance covered in the 
6MWT of more than 54 m (the minimal signiﬁ  cant increase) 
at the end of the rehabilitation program; this improvement 
Table 4 SGRQ scores for control and active groups
Group    S1 A1 I1 T1  S2 A2  I2 T2  Dif.S  Dif.A  Dif.I  Dif.T
Control    42.33 64.83 47.3  58.5  39.5  63.66  46  57  −2.83  −1.2  −1.3  −1.5
  ±   ±   ±   ±   ±   ±   ±   ±   ±   ±   ±   ± 
  (2.9)  (2.4)  (3.3) (3.7) (2.7) (3.3) (4.1) (3.0) (0.8)  (0.3)  (0.9) (0.4)
Active   38.2  63.3  52.1 59.6 31.9 57.8 47.2 47.3 −7.7  −5.5  −4.9  −12.3
  ±   ±   ±   ±   ±   ±   ±   ±   ±   ±   ±   ± 
  (2.6)  (2.1)  (3.0) (3.2) (3.3) (2.3) (2.6) (2.3) (1.2)  (0.9)  (0.4) (1.4)
Notes: Data are presented mean ± SD; Study Entry Score S1, A1,I1,T1; 14-week Score S2,A2,I2,T2; Difference of score between study entry and after 14 weeks: Dif.S, Dif.A, 
Dif.I, Dif.T.
Abbreviations: S, Symptom; A, Activity; I, Impact; T, Total.
Table 5 Six-minute walking distances for control and active 
groups
Group   Study entry  14-week  Difference
Control   273 ± (19)m  281 ± (22)m  +8 ± (8.6)m
Active   284 ± (18)m  330 ± (19)m  +46 ± (9.2)m
Notes: Data are presented as mean ± SD.International Journal of COPD 2008:3(1) 160
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may have been due to changes in ventilatory capacity and 
improved respiratory patterns.
Our study has shown also, that patients submitted the 
proposed protocol of rehabilitation presented a signiﬁ  cant 
improvement in quality of life as assessed by the SGRQ, 
which was sensitive in detecting these improvements in qual-
ity of life in our patients with COPD. Nevertheless, there are 
several different instruments for measuring health – related 
quality of life in patients with COPD, of which the chronic 
respiratory disease questionnaire, the SGRQ, and the baseline 
dyspnoea index have been demonstrated to be reproducible, 
valid, and responsive (Curtis et al 1994). The most com-
prehensive disease-speciﬁ  c instrument, the chronic respira-
tory disease questionnaire (Guyatt et al 1989), deals with 
perceptions of dyspnoea, fatigue, patients’ sense of control 
over their disease, and emotional dysfunction. It depends 
in part on each patient identifying areas of life disturbed by 
disease, so that the result is individualized, and is difﬁ  cult 
to compare between different studies. The SGRQ has the 
advantage of being a standardized questionnaire, allowing 
comparison between studies and different interventions, and 
hence was chosen for this study. The SGRQ routinely takes 
about 10 min to administer, which in our study was super-
vised by an observer blinded to the patients’ randomization. 
Each component of the questionnaire gives a weighted score 
between 0 and 100, including the total, with normal values 
in healthy individuals of 7 for each component. A change 
of 4 points in the total score has been shown to represent 
the minimally clinically significant change (Jones et al 
1991; Quirk et al 1991). Thus our results, with reduction in 
total scores (within the active group) of 12.3 at the end of 
14 weeks clearly represent clinically signiﬁ  cant beneﬁ  ts from 
the treatment program. We can say the same thing for the 
other components (symptoms, activity, and impact) which 
gave signiﬁ  cant reductions within the active group too. They 
are comparable with the changes observed by (Grifﬁ  ths 
et al 2000). That group studied the effect of outpatient 
rehabilitation in patients with COPD, and observed a mean 
improvement in total SGRQ score of 9.4 points at 6 weeks, 
which remained signiﬁ  cant at 4.8 points after one year.
Studies of standard respiratory rehabilitation programs 
have shown that aerobic physical conditioning does not 
modify lung function (American College of Chest Physicians 
1997; American Thoracic Society 1999). Consequently, the 
fact that lung function is not altered by pulmonary reha-
bilitation is broadly accepted in medical literature. Kakizaki 
et al showed that FVC is increased by stretching respiratory 
muscles (Kakizaki et al 1999). The FVC of an individual 
is dependent on lung elastic recoil, chest wall elasticity 
and respiratory muscle ﬁ  tness. Exercises in our study are 
not designed to improve respiratory muscle stretching and 
have no effect on lung tissue structure. Thus, it is possible 
Table 6 Pulmonary function for control and active groups
Parameters Active  group      Control  group
   Study entry  14-week  Difference   Study entry  14-week  Difference
FVC,% 86.1  ±   81.7 ±   −4.4 ±   78.7 ±   79.65 ±   +0.95 ± 
Predicted (17.8)  (3.5)  (9.8)  (3.5)  (3.3)  (1.4)
FEV1,% 41.9  ±   41.3 ±   −0.8 ±   43.33 ±   44.83 ±   +1.5 ± 
Predicted   (2.6)  (3.6)  (0.4)  (3.6)  (4.17)  (1.6)
RV,% 160.6  ±   163 ±   +2.4 ±   154.66 ±   151 ±   −3.66 ± 
Predicted (5.6)  (4.7)  (1.3)  (3.64)  (2.36) (0.8)
Notes: Data are presented as mean ± SD.
Table 7 BODE index scores
 Active  group      Control  group 
  Baseline 14  weeks  Difference  Baseline 14  weeks  Difference
FEV1 (%)  2 ± (0.3)  2 ± (0.2)  0  2 ± (0.42)  2 ± (0.58)  0
D.6MWT(m) 1  ± (0.4)  1 ± (0.33)  0  1 ± (0.29)  1 ± (0.46)  0
Dyspnoea 2  ± (0.6)  0 ± (0.8)  −2 2  ± (0.7)  2 ± (0.8)  0
BMI 1  ± (0.4)  1 ± (0.6)  0  1 ± (0.39)  1 ± (0.42)  0
BODE index  6 ± (0.44)  4 ± (0.38)  −2 6  ± (0.7)  6 ± (0.6)  0
Notes: Data are presented as scores (from 0 to 10); Data are presented as mean ± SD.International Journal of COPD 2008:3(1) 161
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that the Kakizaki exercises modiﬁ  ed chest wall elasticity or 
respiratory muscle strength.
A recent multicenter, community-based experience 
(California Pulmonary Rehabilitation Collaborative Group 
2004) (also known as the California Collaborative) included 
nine centers of 647 patients, which showed consistent ben-
eﬁ  ts in dyspnoea and quality of life as well as a reduction in 
health-care utilization (eg, physician visits, telephone calls, 
hospital days, and urgent care visits) over an 18-month 
follow-up period.
Guidelines (American College of Chest Physicians 1997; 
American Thoracic Society 1999) on pulmonary rehabilita-
tion have reviewed the strength of the evidence for current 
practices. One analysis gave the strength of improvement in 
quality of life with rehabilitation as grade B, and outlined 
three randomized controlled trials addressing this topic; 
of these, only one trial used a control group with no reha-
bilitation or educational input and was also outpatient-based 
rehabilitation (Wijkstra et al 1994). The American Thoracic 
Society review (American Thoracic Society 1999) did not 
identify any further studies of the type described in the cur-
rent study, namely exclusively outpatient-based rehabilitation 
with a control group not receiving anything other than 
standard medical care. Our search in the literature revealed 
two articles (Engostrom et al 1999; Grifﬁ  ths et al 2000) 
that are of this type. The regimen described by (Grifﬁ  ths 
et al 2000) was very similar to our own, involving a 6-week 
outpatient-based program, and showed improvements in 
quality of life that were sustained for a year. Engstrom and 
colleagues (1999) also used an initial 6-week rehabilitation 
program, but they described a gradual transition from this to a 
home based program and also incorporated booster sessions. 
It is of interest that in their study, no signiﬁ  cant effect was 
seen on the scored achieved with the SGRQ, although minor 
improvements in exercise tolerance were observed.
Finally, we used BODE index (Bartolome et al 2004) 
as a predictor of the risk of death from any cause, not only 
from respiratory causes. It is useful because it includes one 
domain that quantiﬁ  es the degree of pulmonary impairment 
(FEV1), one that captures the patients’ perception of symp-
toms (the MMRC dyspnoea scale) which we chose because it 
predicts the likelihood of survival among patients with COPD 
(Nishimura et al 2002), and two independent domains (the 
distance walked in six minutes and the body mass index) that 
express the systemic consequences of COPD.
The present study contributes additional information 
to the knowledge regarding the beneﬁ  ts of the pulmonary 
rehabilitation on exercise capacity and the quality of life. 
It supports previous data that an outpatient program can 
provide beneﬁ  ts to patients with COPD.
Our current study was not designed to determine whether 
outpatient pulmonary rehabilitation reduces exacerbations 
and hospital admissions in chronic obstructive pulmonary 
disease patients. Further studies should be performed in order 
to clarify these questions.
In conclusion, this study demonstrated in a controlled 
study that a 14-week program of outpatient-based reha-
bilitation of 3h/wk achieved a clinically signiﬁ  cant increase 
in patient’ quality of life, also in exercise tolerance and a 
decrease in the risk of death as measured using BODE index 
without any changes in the pulmonary function.
Thus, another program of rehabilitation might be added 
to the other programs, and also may represent yet another 
valuable tool in pulmonary rehabilitation.
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